German Health Insurers Demand Stronger Action on Rising Medicine Prices

Health insurance funds in Germany have called on the government to take more decisive measures to curb soaring pharmaceutical prices, highlighting an urgent need for health policy reform. Oliver Blatt, head of the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), criticized the government's timid response, noting that Germany has the second highest drug prices worldwide, only behind the United States. He emphasized that higher prices have not resulted in improved healthcare services, as many German pharmaceutical companies already manufacture their products abroad in countries like China and India.

In 2022, statutory health insurers' spending on medicines reached 58.5 billion euros, surpassing expenditures on outpatient medical care and representing the second largest expense area in the health system. Notably, costs for new medications have doubled over the past 12 years, underscoring the financial strain on the healthcare system. Blatt asserted that price reductions are possible without pharmaceutical manufacturers relocating abroad.

In response to these challenges, Federal Health Minister Nina Warken (CDU) has established an expert commission tasked with proposing cost-saving measures in the healthcare sector by the end of March. This move signals government recognition of the need to manage escalating expenses more effectively.

This call for urgent reforms coincides with broader economic pressures in Germany, including rising energy costs and social security burdens that threaten economic recovery. Observers suggest that comprehensive social security and health insurance reforms, alongside targeted fiscal policies, are critical to stabilizing both the economy and public services. As the country faces these intertwined challenges, health insurers and policymakers alike emphasize the importance of decisive and balanced action to protect both the quality and affordability of healthcare services.